NEW White Paper: A platform for screening drugs to treat sickle cell disease and other hemoglobinopathies
#HbF Protein Assay performed by ReachBio Research Labs.
The HbF #drug screening platform is a serum-free assay format where unaffected primary human bone marrow cells can be expaned in the presence of various cytokines in a two-step culture system
- Initial Stage: Synchronization of the cells
- Second Stage: Induce differentiation along the erythroid (RBC) lineage
- Read out by FACS
This is part of the great service portfolio of ReachBio.
The White paper describes the development of a serum-free assay platform where unaffected primary human bone marrow cells can be expanded in the presence of various cytokines in a two-step culture system. This serum-free assay platform offers a direct measurement of the HbF protein, using two methods in response to treatment with HU as shown, and additionally with other HbF inducers (data not shown). This differs from other approaches looking at increases in transcript numbers or other indirect measurements. This in vitro assay will facilitate the ability to examine new potential drug therapies, both alone and in combination with HU, on HbF induction. Although affected donor samples were not available in the current study, this assay may be used to assess HU responsiveness in some SCD patients and to identify other patient-specific drug options.
Pleas call Peter +49 89 517 286 59 -0 or send us an email to email@example.com with the line “ReachBio White Paper SCD” and we will send you the WhitePaper – asap.